VYCO Vycor Medical Inc (QB)

Vycor Medical, Inc. (OTCBB: VYCO), a medical device company that designs, develops and markets next generation neurosurgery devices, announced today that its China Patent Application No. ZL200680056889.9 has been granted. This action provides Vycor patent rights with respect to its innovative ViewSite Brain Access System (VBAS) in China.

ViewSite Brain Access System (VBAS) is the Company's first product, a new generation system that allows surgeons access to deep lesions in the brain. Kenneth Coviello, Vycor's CEO, commented, "We are very pleased with the news of the patent protection we have received in China. Vycor has applied for SFDA approval in China which would allow us to begin marketing. We are hopeful this will also be granted in the near future."

In contrast to development in other surgical technologies, the Company's product addresses a market that has not changed materially in over 50 years. Published literature suggests that existing standard brain retractors can cause brain damage and/or prolonged patient recovery with the incidence of contusion or infarction from brain retraction in approximately 10% in cranial surgery and 5% in intracranial procedures. Pressure at the retractor blade tip is said to be responsible for 22% of infarctions as determined by CT scans. Given that there are an estimated 600,000 brain surgeries annually worldwide, this is a very sizeable issue which could result in a sizeable potential addressable market for the Company.

Vycor and its subsidiary NovaVision maintain a portfolio of patent protection on their methods and apparatus in the form of issued patents and applications, both domestically and internationally. In the U.S., the Group has a total of 8 issued patents and 8 pending applications. The international patent portfolio includes 8 issued patents and 26 pending applications.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.VycorMedical.com.

About Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (OTCBB: VYCO) is a medical device company committed to making neurological brain, spinal and other surgical procedures safer and more effective. The company's flagship, Patent Pending ViewSite™ Surgical Access Systems represent an exciting new minimally invasive access and retraction system that holds the potential for speedier, safer and more economical brain, spinal and other surgeries and a quicker patient discharge. Vycor's innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery, and add tangible value to the professional medical community. Vycor is ISO 13485:2003 compliant, has FDA 510(K) clearance for brain and spine surgeries, and CE marketing and HPB licensing in Canada. In December of 2010 the company purchased the assets of NovaVision Inc. www.novavision.com. NovaVision's Vision Restoration Therapy ("VRT") is an FDA cleared, patented, non invasive medical device that helps to restore vision in stroke or traumatic brain injuries (TBI) patients with visual deficits. Potential visual field deficits include (but are not limited to) hemianopia, quadrantatnopia, and scotoma.

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast," "anticipate," "estimate," "project," "intend," "expect," "should," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the abovementioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Contact: Karen Coviello 561-558-2018 Email Contact